$ACRV
Acrivon Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$1.89
▲+11.18%+$0.190
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateAcrivon Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is ACRV up today? It is at $1.89 (+11.18%), and our scanner flagged it 12 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ACRV spikes, and full due diligence on ACRV — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ACRV 12 times in the last 30 days. Create a free account to track $ACRV, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on ACRV from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystAcrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data CatalystsReported Cash, cash equivalents, and marketable securities of $90.0 million as of June 30, 2026 expected to fund operations into fourth quarter of 2027Reported Net loss for the quarter ended June 30, 2026 was $18.0 million compared to a net loss of $21.0 million for the same period in 2025.Reported Research and development expenses were $13.8 million for the quarter ended June 30, 2026 compared to $16.2 million for the same period in 2025. The difference is primarily driven by two, from an SEC filing. Read it →| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Levin Michaela Officer | Acquired (grant/award) | +30K 0.07% of company | n/a | 30K | n/a | Aug 31, 26 |
Blume-Jensen Peter Officer | Sold (automatic/other) | -14K 0.03% of company | sold 0.6% | 2.23M | $31K at $2.21 | Aug 25, 26 |
Blume-Jensen Peter Officer | Sold (automatic/other) | -1K | sold <0.1% | 2.24M | $2K at $2.01 | Aug 18, 26 |
Blume-Jensen Peter Officer | Sold (automatic/other) | -484 | sold 0.1% | 386K | $973 at $2.01 | Aug 18, 26 |
Devroe Eric Officer | Sold (automatic/other) | -604 | sold 0.4% | 146K | $1K at $2.01 | Aug 18, 26 |
Gamelin Erick Officer | Sold (automatic/other) | -400 | sold 0.8% | 53K | $804 at $2.01 | Aug 18, 26 |
Miller Mary Officer | Sold (automatic/other) | -185 | sold 0.2% | 82K | $372 at $2.01 | Aug 18, 26 |
Peterson Katharine Officer | Sold (automatic/other) | -101 | sold 0.6% | 18K | $203 at $2.01 | Aug 18, 26 |
Levy Adam D. Officer | Sold (automatic/other) | -1K | sold 1.7% | 66K | $2K at $1.57 | Aug 4, 26 |
Miller Mary Officer | Sold (automatic/other) | -573 | sold 0.7% | 82K | $1K at $1.76 | Jul 21, 26 |
Blume-Jensen Peter Officer | Sold (automatic/other) | -14K 0.03% of company | sold 0.6% | 2.25M | $25K at $1.79 | May 21, 26 |
Blume-Jensen Peter Officer | Acquired (grant/award) | +180K 0.4% of company | added 8.7% | 2.26M | n/a | May 18, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on ACRV from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
ACRV last traded at $1.89, up 11.18% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Acrivon Therapeutics, Inc. Common Stock (ACRV) is next expected to report earnings on Thursday, November 12, 2026, about 53 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The ACRV Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ACRV 12 times in the last 30 days.
ACRV (Acrivon Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $79M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ACRV for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ACRV discussion
Sign in to ask a question or join the discussion.